Alphabet Faces Dual Setbacks as Pharma Partnership Dissolves and EU Launches Fresh Probe

Alphabet Inc., the parent company of Google, encountered significant headwinds on Thursday as two separate challenges emerged simultaneously. The technology conglomerate saw the collapse of a multi-billion dollar pharmaceutical collaboration while European regulators initiated a new investigation into its business practices, creating a perfect storm of negative developments.

Regulatory Scrutiny Intensifies Under Digital Markets Act

The European Commission has turned its regulatory attention to Google’s treatment of news publishers within its search results. The investigation will examine whether the tech giant systematically disadvantages publishers who incorporate sponsored content or commercial third-party articles in their offerings.

This probe falls under the jurisdiction of the Digital Markets Act (DMA), one of Brussels’ most stringent regulatory frameworks. The potential consequences for non-compliance are substantial, with penalties reaching up to 10% of global annual revenue. For Alphabet, this could translate to a financial impact measuring in the tens of billions of dollars.

Biotech Venture Collapses After Decade of Investment

In a separate but equally significant development, Alphabet’s biotechnology subsidiary Calico has lost its long-standing pharmaceutical partner AbbVie. The drug manufacturer has withdrawn from the collaboration after more than ten years of joint research, marking the end of an enterprise that consumed over $1.75 billion in funding.

The partnership, originally established in 2013 with the objective of developing groundbreaking therapies for age-related diseases, had been extended as recently as 2021 with a potential valuation of $3.5 billion. The collaboration failed to yield any approved medications throughout its duration. AbbVie’s strategic repositioning toward more complex gene therapies prompted the dissolution.

Should investors sell immediately? Or is it worth buying Alphabet?

For Alphabet’s “Other Bets” segment, which has consistently underperformed expectations, this represents a substantial setback.

Mounting Challenges Despite Strong Performance

These developments arrive during a period when Alphabet’s stock had been demonstrating robust performance, reaching record highs earlier in the week fueled by enthusiasm surrounding artificial intelligence initiatives and cloud computing services.

The dual challenges highlight emerging vulnerabilities at the edges of Alphabet’s operations despite continuing strength in core business areas. The failed Calico partnership underscores the considerable difficulties of establishing footing within the high-risk biotechnology sector, while regulatory pressures continue to mount on multiple fronts. Beyond the new EU investigation, additional antitrust proceedings remain ongoing, including several within the United States.

Market analysts maintain a generally positive outlook on Alphabet’s fundamental position, citing strong third-quarter performance and significant potential in artificial intelligence development. However, the combination of a failed billion-dollar investment and intensified regulatory scrutiny is expected to dampen investor sentiment in the near term.